obesity

Novo focuses on new obesity therapy Semaglutide
Novo focuses on new obesity therapy Semaglutide
GoInPharma
Novo Nordisk
obesity
semaglutide
Flag link:
Can Novo’s blockbuster push on obesity drug semaglutide succeed where others failed?
Can Novo’s blockbuster push on obesity drug semaglutide succeed where others failed?
Endpoints
Novo Nordisk
semaglutide
obesity
Flag link:
Novo Nordisk says obesity drug helps up to 13.8 percent weight loss in phase 2 trial
Novo Nordisk says obesity drug helps up to 13.8 percent weight loss in phase 2 trial
Reuters
Novo Nordisk
obesity
semaglutide
Flag link:
J&J unveils new obesity, arthritis collaborations, shares its molecule library
J&J unveils new obesity, arthritis collaborations, shares its molecule library
Fierce Biotech
JNJ
obesity
rheumatoid arthritis
molecules
molecule library
drug development
Flag link:
Novo Nordisk preps Saxenda sales drive in Latin America after its 'phenomenal' Q1
Novo Nordisk preps Saxenda sales drive in Latin America after its 'phenomenal' Q1
Fierce Pharma
Novo Nordisk
Saxenda
Latin America
obesity
Flag link:
Zafgen starts comeback with first data on replacement weight loss drug
Zafgen starts comeback with first data on replacement weight loss drug
Fierce Biotech
Zafgen
obesity
beloranib
ZGN-1061
Flag link:
Vivus Announces Positive Ruling In Qsymia Litigation - Will It Matter?
Vivus Announces Positive Ruling In Qsymia Litigation - Will It Matter?
Seeking Alpha
Vivus
Qsymia
obesity
Flag link:
Zafgen shares drop more than 40% as drug focus shifted
Zafgen shares drop more than 40% as drug focus shifted
Marketwatch
Zafgen
beloranib
ZGN-1061
obesity
Flag link:
Arena Pharma stock rises 8.8% after weight-loss drug is approved
Arena Pharma stock rises 8.8% after weight-loss drug is approved
Marketwatch
Arena Pharmaceuticals
FDA
obesity
Eisai
Belviq XR
Flag link:
Arena - Anti-Obesity Drug Lorcaserin Approved In Mexico
Arena - Anti-Obesity Drug Lorcaserin Approved In Mexico
Seeking Alpha
Arena Pharmaceuticals
lorcaserin
obesity
Mexico
Flag link:
Vivus: Qsymia Sales Close Out Q2 With Worst Sales Volume In 2 Years
Vivus: Qsymia Sales Close Out Q2 With Worst Sales Volume In 2 Years
Seeking Alpha
Vivus
Qsymia
obesity
Flag link:
Orexigen - Contrave Sales Present Troubling Data
Orexigen - Contrave Sales Present Troubling Data
Seeking Alpha
Orexigen
Contrave
obesity
Flag link:
Vivus - Qsymia Sales Still Trending In The Wrong Direction
Vivus - Qsymia Sales Still Trending In The Wrong Direction
Seeking Alpha
Vivus
Qsymia
obesity
Flag link:
FDA approves weight-loss device that drains out undigested food
FDA approves weight-loss device that drains out undigested food
Stat
FDA
devices
obesity
AspireAssist
Aspire Bariatrics
Flag link:
Zafgen up 6% after weight loss drug has positive late-stage trial results
Zafgen up 6% after weight loss drug has positive late-stage trial results
Marketwatch
Zafgen
obesity
beloranib
diabetes
Flag link:
Orexigen struggles to stay afloat as obesity market stagnates
Orexigen struggles to stay afloat as obesity market stagnates
BioPharma Dive
Orexigen
obesity
Contrave
Vivus
Qsymia
Takeda
Flag link:
Arena Investors: What To Consider As Anti-Obesity Drugs Fizzle
Arena Investors: What To Consider As Anti-Obesity Drugs Fizzle
Seeking Alpha
Arena Pharmaceuticals
obesity
Orexigen
Belviq
Eisai
Vivus
Novo Nordisk
Qsymia
Victoza
Flag link:
With weight-control peers flailing, Shire keeps growing Vyvanse
With weight-control peers flailing, Shire keeps growing Vyvanse
Fierce Pharma
Shire
Vyvanse
obesity
ADHD
Flag link:
Orexigen: Contrave Sales Flatten Out At End Of Q1
Orexigen: Contrave Sales Flatten Out At End Of Q1
Seeking Alpha
Orexigen
Contrave
obesity
Novo Nordisk
Vivus
Arena Pharmaceuticals
Flag link:
Arena: Belviq Sales Still Slow - Will Eisai Stick Around?
Arena: Belviq Sales Still Slow - Will Eisai Stick Around?
Seeking Alpha
Arena Pharmaceuticals
Belviq
Eisai
obesity
Flag link: